Zühlke Group
VC Fund
Schlieren, Switzerland
Zühlke Group is a VC fund in Schlieren focused on Genetics and Biotechnology. Zühlke assists companies in implementing their vision from concept to market successZühlke helps companies establish new ventures, by covering all phases of the business innovation process and accompanies products and applications from the initial idea through to the implementation and operation.The company was founded in Switzarland in 1968,and as of today, Zühlke runs local teams in Austria, Germany, Serbia, Switzerland, and the United Kingdom.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Zühlke Group invests in
Stages Zühlke Group invests in
Countries Zühlke Group invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Investment Focus
Industry
- Genetics 1 (100%)
- Biotechnology 1 (100%)
- Manufacturing 1 (100%)
- Pharmaceutical 1 (100%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andreas Griesser
Head of LabScience, Pharma & Biotech
|
Head of LabScience, Pharma & Biotech | Total investments: 0 | Find email | |
Antonio Oro
Lead Consultant AI Solution Center
|
Lead Consultant AI Solution Center | Total investments: 0 | Find email | |
Daniel Diezi
Head of Life Sciences & MedTech
|
Head of Life Sciences & MedTech | Total investments: 0 | Find email | |
Francisco Lopes
Advanced Software Engineer
|
Advanced Software Engineer | Total investments: 0 | Find email | |
Jon H. Hoem
Senior Business Solution Manager
|
Senior Business Solution Manager | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Limula
|
Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production. | $6.8M / Seed / May 21, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Zühlke Group invest in?
Zühlke Group invests primarily in Genetics, Biotechnology and Manufacturing startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Zühlke Group?
Public channels for Zühlke Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Zühlke Group?
The team at Zühlke Group includes Andreas Griesser (Head of LabScience, Pharma & Biotech), Antonio Oro (Lead Consultant AI Solution Center) and Daniel Diezi (Head of Life Sciences & MedTech), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
